Solasia Pharma, The Current Fiscal Year Net Income Loss Widened in Downward Revision

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Dec 27, 2024 4:00 pm JST Revision

4597 Solasia Pharma K.K. 【IFRS】

Guidance Update Report

Solasia Pharma K.K. <4597> [TSE Growth] announced a performance revision after the market closed on December 27th (16:00). The consolidated net income/loss for the fiscal year ending December 2024 has been revised downward from an expected loss of 0.67 billion yen to a loss of 1.15 billion yen (compared to a loss of 1.11 billion yen in the previous period), indicating an expansion in the loss margin.

Based on the downwardly revised full-year plan announced by the company, our calculation indicates that the July to December period (2H) consolidated net income/loss has been revised downward from an expected loss of 0.06 billion yen to a loss of 0.53 billion yen (compared to a loss of 0.67 billion yen in the same period of the previous year), indicating an expansion in the loss margin.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2024 Prev	1,303	-64	-48	-64	-0.3	0	Aug 14, 2024	IFRS
Jul - Dec, 2024 New	88	-539	-523	-539	-2.7	0	Dec 27, 2024	IFRS
Revision Rate	-93.2%	-742.2%	-989.6%	-742.2%	-834.5%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2024 Prev	1,375	-675	-675	-675	-3.1	0	May 15, 2024	IFRS
Dec, 2024 New	160	-1,150	-1,150	-1,150	-5.8	0	Dec 27, 2024	IFRS
Revision Rate	-88.4%	-70.4%	-70.4%	-70.4%	-86.8%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2023	88	-677	-685	-675	-4.0	0	Feb 14, 2024	IFRS
Jul - Dec, 2024 Guidance	88	-539	-523	-539	-2.7	0	Dec 27, 2024	IFRS
YoY	0.0%	+20.4%	+23.6%	+20.1%	+32.6%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2022	1,092	-2,470	-2,492	-2,548	-16.8	0	Feb 14, 2023	IFRS
Dec, 2023	617	-1,139	-1,135	-1,112	-6.6	0	Feb 14, 2024	IFRS
Dec, 2024 Guidance	160	-1,150	-1,150	-1,150	-5.8	0	Dec 27, 2024	IFRS
YoY	-74.1%	-1.0%	-1.3%	-3.4%	+12.5%